SCHEMBL379405

SCHEMBL379405

COc1cc(OC)nc(CCl)n1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 3/20 0.41
CYP1A2 P05177 2/20 0.39
PDE2A O00408 3/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
POLB P06746 2/20 0.37
JAK2 O60674 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
TDP1 Q9NUW8 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13230223 0.89 SMN1; SMN2 (0.41) SMN1; SMN2LMNACYP1A2PDE2AKDM4E
SCHEMBL8892697 0.87 SLC6A3 (0.47) SMN1; SMN2LMNACYP1A2ALDH1A1MEN1
SCHEMBL5502085 0.82 LMNA (0.41) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A
SCHEMBL8343522 0.78 LMNA (0.45) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A
SCHEMBL7009144 0.77 NPC1 (0.40) SMN1; SMN2LMNAKDM4EALDH1A1NPC1
SCHEMBL4595225 0.76 LMNA (0.43) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A
SCHEMBL10048775 0.76 LMNA (0.43) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A
SCHEMBL13738921 0.76 CYP1A2 (0.44) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A
SCHEMBL4918384 0.76 LOXL2 (0.44) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A
SCHEMBL15752122 0.76 LMNA (0.48) SMN1; SMN2LMNAL3MBTL1CYP1A2PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098060-A1 MACROCYCLIC CFTR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2026-04-09 US disclosed
US-20250388592-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2025-12-25 US disclosed
EP-4587443-A1 MACROCYCLIC CFTR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2025-07-23 EP disclosed
EP-4568968-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2025-06-18 EP disclosed
WO-2024056798-A1 MACROCYCLIC CFTR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-03-21 WO disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed
EP-2463277-B1 METHOD FOR PRODUCING 4,6-DIALKOXY-2-CYANOMETHYLPYRIMIDINE AND SYNTHETIC INTERMEDIATE THEREOF KUMIAI CHEMICAL INDUSTRY CO (JP) 2017-11-08 EP disclosed
US-20170114075-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-04-27 US disclosed
US-9598396-B2 Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-03-21 US disclosed
US-9458178-B2 Spiro-oxindole compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2016-10-04 US disclosed
US-20020025976-A1 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-02-28 US disclosed
EP-1181283-A1 DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-02-27 EP disclosed
WO-2000075120-A1 DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2000-12-14 WO disclosed
US-5821368-A Method for preparing pyrimidin-2-ylacetic acid esters LONZA AG (CH) 1998-10-13 US disclosed
EP-0819680-A2 Process for the preparation of esters of pyrimidin-2-acetic acid LONZA AG (CH) 1998-01-21 EP disclosed
WO-1996041799-A1 SULPHONAMIDES AS HERBICIDES AND PLANT-GROWTH REGULATORS HOECHST SCHERING AGREVO GMBH (DE) 1996-12-27 WO disclosed
EP-0353640-B1 Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators HOECHST SCHERING AGREVO GMBH (DE) 1995-04-12 EP disclosed
US-5186736-A Pre- and postemergence HOECHST AKTIENGESELLSCHAFT (DE) 1993-02-16 US disclosed
US-5053072-A HETEROCYCLIC N-ACYLSULFONAMIDES, AND THEIR USE AS HERBICIDES OR GROWTH REGULATORS HOECHST AKTIENGESELLSCHAFT (DE) 1991-10-01 US disclosed
EP-0353640-A2 Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators Hoechst Schering AgrEvo GmbH (DE) 1990-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114075-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV3, TRPV1, TRPC3 SMN1; SMN2 289/4885LMNA 1296/4885L3MBTL1 2721/4885
US-20260098060-A1 MACROCYCLIC CFTR MODULATORS CFTR, CLIC1, ARRB1 SMN1; SMN2 4573/4885LMNA 2343/4885L3MBTL1 4158/4885
US-20020025976-A1 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use BRAF, CDK2, CHUK SMN1; SMN2 4704/4885LMNA 3774/4885L3MBTL1 4722/4885
US-20250388592-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SNCA, CHRNA6, CHRNA5 SMN1; SMN2 95/4885LMNA 183/4885L3MBTL1 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.